CYP19A1 and breast cancer: Thus, even though ovary ablation (OA) was shown to reduce breast cancer relapse (in combination with the use of either tamoxifen or aromatase inhibitors) in high-risk women, adjuvant OA should still be utilized with careful considerations [30].